Stock Alert: BeiGene Hits New High

Shares of Chinese biotechnology company BeiGene, Ltd. (BGNE) are climbing more than 8% Monday morning to hit a new high of $215.85.

Sunday, the company priced the previously announced share offering of about 145.84 million shares at $14.2308 per share or $185 per American Depository share, which is 5.6% lower than its closing price on Friday.

The net proceeds of about $2.07 billion is intended to be used for working capital and general purposes.

The offering is expected to close by July 15, 2020.

BeiGene's blood cancer therapy, Brukinsa (Zanubrutinib) had won the FDA approval in November last year and became the first Chinese cancer treatment approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues... Shares of ASML Holding N.V. were gaining more than 1 percent in Amsterdam trading after the Dutch semiconductor equipment maker reported Wednesday higher profit and net sales in its fourth quarter. The company also projects higher sales in fiscal 2022, and a 100 percent increase in total dividend.
Follow RTT